The Life Science Sector Emerging As An Asset Class
Better Loan Solutions in Mornington Peninsula • Learning Centre • Insights
Better Loan Solutions in Mornington Peninsula • Learning Centre • Insights
Demand for life science assets is on the rise in Australia as the ageing population will continue to put more demand on the growing sector,
according to a report from CBRE.
The report also found that the industry is emerging as a major growth sector, with increased levels of investment from pharmaceutical
companies and the government contributing to rising demand.
There is currently a significant shortage of quality life science facilities in Australia and only a small number of investors are seeking
exposure in this emerging asset class. The life sciences industry includes medical laboratories, medical research organisations,
pharmaceutical companies, and biotech firms.
Sandro Peluso, CBRE's Director of the Australian Healthcare and Social Infrastructure team, said that there is a growing appetite for life
sciences venture capital and private investment opportunities.
He said that while investors are starting to seek quality assets in the life science field, the sector is still relatively new.
The report noted that life science operators often commit to long lease terms of 10-15 years (or more) due to the capital needed to set up
such facilities. Additionally, with record low vacancy rates, having a life science operator in a facility is likely to drastically increase
its market appeal when it comes time to sell.
One of the key reasons for future growth is the rise in Australia’s average age, which is expected to increase significantly and lead to
rising demand for medical treatment and life-extending products. According to the report, Australia's population aged 85 and above is
expected to increase from 534,000 in 2021 to 1.28 million by 2041, representing an increase of 140%.
The Australian Government uses the National Health and Medical Research Council, Biomedical Translation Fund, and the Medical Research Future Fund, alongside university grants, to fund health and medical research.
Since the beginning of 2010, total government research spending allocated for health sits at 16.5%, compared to a median of 7.8% in other
countries
Pharmaceutical companies are also expanding their production capabilities in Australia, including R&D, manufacturing and distribution.
On top of that, life sciences businesses are also active in real estate acquisition, disposition, and debt and equity recapitalisation
strategies across the sector.
Mr Peluso said developers and investors are also focused on the sector's strong underlying fundamentals.
He said despite the significant shortage of quality life science facilities in Australia, it is becoming a sector of interest for investors
as it continues to grow due to the rising demand for medical treatment and the increase in government funding.
Our in-house mortgage broking service makes your mortgage and lending needs so much easier,
minimising the discord between accountant, lender and product advice.
WEBINAR 25 SEPT // 12PM
The final session focuses on the changing legal environment, highlighting recent amendments to the Fair Work Act, capturing independent
contractors under workers' compensation schemes, payroll tax considerations, superannuation compliance, and practical steps to mitigate
risks.
WEBINAR 11 SEPT // 12PM
In the third session, we'll delve into superannuation guarantee changes, including proposed changes to payday superannuation, new rates and
bases, and the impact on SG liability. Gain insights into employer deductions, termination of employment considerations and more.
WEBINAR 4 SEPT // 12PM
Master allowances and reimbursements, understand their PAYG and super guarantee implications, and learn to navigate travel vs.
living-away-from-home allowances. Gain insights into FBT considerations, new ATO record-keeping requirements, and effective salary packaging
arrangements.